Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases
Observational · No treatment assigned · 1 site · University Hospital, Grenoble
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflammatory Bowel Disease (IBD). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Men and women over 18
- Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
- Patient not objecting to the REPRO-MICI study
There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 30 participants are expected to take part.
- Start date: 2026-07-01 (planned).
- Main results expected around 2028-04-30 (estimate from the record).
- 1 study site listed in France.
Main thing being measured
- Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated (up to 2 years)
In the researchers’ words
Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in…
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflammatory Bowel Disease (IBD) |
| Lead sponsor | University Hospital, Grenoble |
| Collaborators | Institute for Advanced Biosciences (IAB), Grenoble |
| Enrollment | 30 (estimated) |
| Start date | 2026-07-01 |
| Primary completion (est.) | 2028-04-30 |
| First posted | 2025-04-25 |
| Last updated | 2026-05-19 |
| Official title | Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases |
| ClinicalTrials.gov ID | NCT06944873 |
Interventions
- Blood test 4 EDTA tubes (Biological)
Blood test 4 EDTA tubes for biological check-up
Full eligibility criteria (from the record)
Inclusion Criteria: * Men and women over 18 * Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up * Patient not objecting to the REPRO-MICI study Exclusion Criteria: * Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress). * Patients with positive HIV, HBV or HCV serology. * Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Grenoble Alpes University Hospital | La Tronche | France |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.